Biotech
DEL MAR, CA: New Integration Delivers Advanced Track-and-Trace Features to Streamline Business Processes, Eliminate Product Mislabeling and Improve Consumer Safety
...
SAN FRANCISCO, CA: $60.0 Million in Revenue Driven by $108.5 Million in Third Quarter U.S. Net Sales of XTANDI; Conference Call Today at 4:30 p.m. Eastern Time
...
SEATTLE, WA: Announces Second Common Stock Purchase Agreement With Aspire Capital for up to $25 Million
...
WASHINGTON, DC: Letter Sent by Six Senators Requests Better Understanding of Government Initiatives Affecting Regenerative Medicine
...
CAMBRIDGE, MA: Ongoing Discussions With FDA Remain a Priority to Advance Eteplirsen Program in Duchenne Muscular Dystrophy; Updated Guidance Lowers Full-Year Operating Loss to $80-90 Million Range; Strong Financial ...
LAVAL, QUEBEC: - PBI-4050 significantly reduces heart fibrosis in chronic kidney disease rat model - Significant reduction of fibrosis in the kidney and liver re-confirmed - Expands potential commercial opportunitie ...
CAMBRIDGE, MA: FDA Questions Dystrophin as a Biomarker Due to Failed Studies of Other Investigational Drugs for DMD; FDA Questions 6-Minute Walk Test Results for Eteplirsen, Suggesting Study Population Should Be Sta ...
TUSTIN, CA: Phosphatidylserine (PS) and CTLA-4 Targeting Antibody Combination Stopped Tumor Growth in 100% of Animals in Preclinical Melanoma Model; Planning Underway for Near-Term Phase I Clinical Trial Evaluati ...
DEERFIELD, IL: DUEXIS(R) Third Quarter Net Revenue of $23.5 Million, an Increase of 122% Versus Q2 2013; Conference Call and Webcast Today, November 8th at 8:00 a.m. ET
...
